Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Sagimet Biosciences Logo
Sagimet Biosciences Growth Score
94
CB Rank
14634
Heat Score
52
Sagimet Biosciences is a biotechnology company that focuses on developing novel therapeutics to treat important diseases.
Founded
obfuscation
PublicPost-IPO Equity San Mateo, California, United States11-50 sagimet.com
Biopharma
Biotechnology
Therapeutics
Overview

Sagimet Biosciences
Total Funding
obfuscation
Growth Score
94
Heat Score
52

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score94
3 pts
in past quarter
Heat Score 52
0 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Sagimet Biosciences

CB Rank
14634
Sagimet Biosciences is a biotechnology company that focuses on developing novel therapeutics to treat important diseases.
Founded
obfuscation
PublicPost-IPO Equity San Mateo, California, United States11-50 sagimet.com
Biopharma
Biotechnology
Therapeutics

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Venture - Series Unknown
OBF
in
obfuscation

Key People

Details

Legal Name Sagimet Biosciences Inc
Also Known As 3-V Biosciences
Operating Status Active
Stock Symbol  NASDAQ:SGMT
Company Type For Profit
Founders  Lucas Pelkmans, Urs Greber
About the Company

Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways. The company has unique expertise in FASN biology and has created a pipeline of proprietary FASN

inhibitors.

Phone Number +1 650.561.8600
Contact Email publicrelations@sagimet.com
Predictions & Insights

Growth Insight

See this Growth Insight
Sagimet Biosciences is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

Denifanstat
An oral, once-daily selective fatty acid synthase (FASN) inhibitor for treating metabolic dysfunction-associated steatohepatitis (MASH).
TVB-3567
A fatty acid synthase (FASN) inhibitor in development for treating acne and certain solid tumors.

Research & Development

Sagimet Biosciences is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 14
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Sagimet Biosciences Logo
Post-IPO Equity - Sagimet Biosciences
8
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Sagimet Biosciences Logo
Post-IPO Equity - Sagimet Biosciences
8
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Sagimet Biosciences Logo
Post-IPO Equity - Sagimet Biosciences
8
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Sagimet Biosciences Logo
Post-IPO Equity - Sagimet Biosciences
8
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Sagimet Biosciences Logo
Post-IPO Equity - Sagimet Biosciences
8
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 14
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Sagimet Biosciences Logo
Post-IPO Equity - Sagimet Biosciences
8
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Sagimet Biosciences Logo
Post-IPO Equity - Sagimet Biosciences
8
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Sagimet Biosciences Logo
Post-IPO Equity - Sagimet Biosciences
8
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Sagimet Biosciences Logo
Post-IPO Equity - Sagimet Biosciences
8
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Sagimet Biosciences Logo
Post-IPO Equity - Sagimet Biosciences
8
obfuscation
— Post-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Coastlands Capital Logo
Coastlands Capital
—
Post-IPO Equity - Sagimet Biosciences Logo
Post-IPO Equity - Sagimet Biosciences
—
Coastlands Capital Logo
Coastlands Capital
—
Post-IPO Equity - Sagimet Biosciences Logo
Post-IPO Equity - Sagimet Biosciences
—
Coastlands Capital Logo
Coastlands Capital
—
Post-IPO Equity - Sagimet Biosciences Logo
Post-IPO Equity - Sagimet Biosciences
—
Coastlands Capital Logo
Coastlands Capital
—
Post-IPO Equity - Sagimet Biosciences Logo
Post-IPO Equity - Sagimet Biosciences
—
Coastlands Capital Logo
Coastlands Capital
—
Post-IPO Equity - Sagimet Biosciences Logo
Post-IPO Equity - Sagimet Biosciences
—
Market Intelligence
People
View Profiles & Contacts
Headcount 11-50 Employee Profiles 6 Board Members and Advisors 9 Contacts 13

Employee Profiles

Board Members and Advisors

News

News and Press

News•May 12, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 12, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 11, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 1, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

7,086
33.75%
 in past month

IT Spend

$43.4KThis year, Sagimet Biosciences is projected to spend $43.4K on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Tom’s Guide Logo
Tom’s Guide
—

Actively Used Products

10Sagimet Biosciences uses 10 technology products and services including HTML5, jQuery, and  Amazon Route 53, according to G2 Stack.

Active Website Tech Count

4Sagimet Biosciences is actively using 4 technologies for its website, according to BuiltWith. These include CommonCrawl Top 50m, Blockthrough, and  ATT.

Total IP

21The intellectual property of Sagimet Biosciences includes 20 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery. Additionally, Sagimet Biosciences has 1 registered trademark in the 'Pharmaceutical, veterinary and sanitary products' class, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Sagimet Biosciences's headquarters? Sagimet Biosciences is located in San Mateo, California, United States.Who invested in Sagimet Biosciences? Sagimet Biosciences has 19 investors including Coastlands Capital and  Great Point Partners.When was the last funding round for Sagimet Biosciences? Sagimet Biosciences closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are Sagimet Biosciences's competitors? Alternatives and possible competitors to Sagimet Biosciences may include BioAge Labs, Avalyn Pharma, and  Q32 Bio.How much funding has Sagimet Biosciences raised to date? Sagimet Biosciences has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(8fe006b 1)
|